Essential thrombocythemia (ET) and polycythemia vera (PV) are hematopoietic stem cell disorders characterized by clonal myeloproliferation, strong inflammatory atmosphere and an increased cardiovascular (CV) burden. The main therapeutic objective in ET and PV is to prevent thrombotic complications. Age more than 60 years and history of thrombosis have been shown to be the most reliable risk factors for future arterial or venous events. Additionally, in ET patients, there is an increased risk of thrombosis in JAK2-mutated patients [[
In recent years, hyperuricemia has gained interest as a determinant of CV risk. Epidemiological and clinical data have shown that hyperuricemia might be associated with an increased risk of venous thromboembolism [[
The association of hyperuricemia and secondary gout in ET and PV has been known for decades. Two mechanisms for hyperuricemia in ET and PV have been proposed; overproduction of SUA as a result of clonal myeloproliferation and reduced SUA clearance caused by impaired renal function [[
This was a single-center, retrospective study. We analyzed a group of newly diagnosed ET and PV patients who presented at General Hospital of Šibenik-Knin County, Croatia, in the period from 2001 to 2019. The diagnoses were reassessed according to the World Health Organization 2016 criteria [[
All statistical analyses were performed with MedCalc Statistical Software
We included 93 patients (52 ET and 41 PV). Median SUA was 333 μmol/L (range 111 − 673), and a total of 29/93 (31%) of patients had SUA above the laboratory reference range (>428.26 μmol/L for adult males, >356.88 μmol/L for adult females) [[
Table 1. Patient characteristics.
Variable SU SU ET/PV (%) 51 (56%)/42 (44%) 27 (53%)/29 (69%) 24 (46%)/13 (31%) 0.116 Age, years 63 IQR (30–80) 64.5 IQR (31–80) 56 IQR (30–76) Sex, male/female (%) 41 (44%)/52 (56%) 28 (50%)/28 (50%) 13 (35%)/24 (65%) 0.159 JAK2 versus CALR/negative (%) 69 (74%)/24 (26%) 45 (80%)/11 (20%) 24 (65%)/13 (35%) 0.096 Palpable splenomegaly, yes/no (%) 32 (34%) 25 (78%)/7 (22%) 31 (51%)/30 (49%) CV risk factors, yes/no (%) 65 (70%) 44 (68%)/21 (32%) 21 (57%)/16 (43%) History of thrombosis, yes/no (%) 23 (25%) 17 (30%)/39 (70%) 6 (16%) /31 (84%) 0.123 Gout, yes/no (%) 6 (6.5%) 6 (10%)/50 (90%) 0/37 (100%) Hydroxycarbamide, yes/no (%) 59 (63%) 38 (68%)/18 (32%) 21 (57%)/16 (43%) 0.279 Acetlysalicylic acid, yes/no (%) 68 (73%) 42 (75%)/14 (25%) 26 (70%)/11 (30%) 0.616 Warfarin, yes/no (%) 7 (7.5%) 4 (7%)/52 (93%) 3 (8%)/34 (92%) 0.863 Leukocytes (×109/L) 8.6 IQR (3.2–17.6) 8.6 IQR (4.2–16.6) 8.2 IQR (3.2–17.6) 0.872 Granulocytes (×109/L) 5.5 IQR (1.1–17.0) 5.4 IQR (1.9–12.7) 5.6 IQR (1.1–17) 0.848 Erythrocytes (×1012/L) 4.7 IQR (3.0–7.9) 5.1 IQR (2.6–9.6) 4.6 IQR (3–7.9) 0.073 Platelets (×109/L) 546 IQR (142–1154) 527 IQR (142–1154) 573 IQR (181–321) 0.089 Hemoglobin (g/L) 138 IQR (87–202) 157 IQR (87–198) 141 IQR (89–202) Hematocrit (%) 0.47 IQR (0.29–0.6) 0.47 IQR (0.29–0.60) 0.43 IQR (0.29–0.6) Creatinine (μmol/L) 78 IQR (45–155) 86 IQR (56–155) 69 IQR (45–113) eGFR (mL/min/1.73m2) 72.5 IQR (35.6–144) 65.3 IQR (35.6–136.2) 91.3 IQR (45–144) LDH (IU/L) 231 IQR (94–696) 231 IQR (94–512) 237 IQR (130–696) 0.591 CRP (mg/L) 2.2 IQR (0.2–15.3) 2.4 IQR (0.2–15.3) 2.1 IQR (0.6–8.8) SUA (μmol/L) 326 IQR (111-673) / / /
- 3 The Chi-square and the Mann–Whitney U test were used. SUA: serum uric acid; ET: essential thrombocythemia; PV: polycythemia vera; JAK2: Janus Kinase 2; CALR: calreticulin; CV: cardiovascular; eGFR: estimated glomerular filtration rate; LDH: lactate dehydrogenase; CRP: C-reactive protein; IU/L: international units per liter; IQR: interquartile range.
1 p values in bold-italic are statistically significant.
Higher SUA was associated with older age (rho = 0.250, p = 0.015), JAK2 mutation (p = 0.033), higher CRP (rho = 0.263, p = 0.010), presence of palpable splenomegaly (p < 0.001), CV risk factors (p = 0.037), history of thrombosis (p = 0.006), higher creatinine (rho = 0.551, p < 0.001), lower eGFR (rho = −0.456, p = 0.001), and the need for hydroxycarbamide therapy (p = 0.036). These associations remained significant when ET and PV patients were analyzed separately (p < 0.050 for all analyses), with the exception of advanced age that correlated positively with SUA only in ET patients (rho = 0.338, p = 0.015). Also, when two disorders were analyzed individually, higher SUA did not correlate with the presence of CV risk factors in both ET and PV patients (p ≥ 0.050). Six patients (6.5%) had gout, and nine (10%) received allopurinol at the time of diagnosis. As expected, these patients had higher SUA (p < 0.050 for both analyses). In both ET and PV patients, SUA did not correlate with sex, leukocyte, granulocyte, erythrocyte and platelet counts, hemoglobin, hematocrit and LDH levels, allopurinol, acetylsalicylic acid, or warfarin therapy.
Median follow-up of ET and PV patients was 62 months (range 3 − 219). Twenty-seven patients (29%) developed thrombosis during the follow-up; 11 (41%) were venous and 16 (59%) arterial (p = 0.336). There was no difference in thrombosis frequency between ET (28.8%) and PV (29.2%) patients (p = 0.919). When we classified patients according to current risk categories, there was a trend for increase in SUA accross R-IPSET categories in ET patients (p = 0.002) (Figure 1). On the other hand, no difference was observed in SUA between low- and high-risk PV patients (p = 0.233). However, PV patients had higher SUA when compared to very low- to intermediate-risk ET patients (p = 0.005). Within the limitations of sample size and small number of thrombotic events, both prognostic systems in survival analyses were able to correctly identify ET and PV patients under increased risk of thrombosis (p = 0.089 for the R-IPSET risk score, and p = 0.003 for the PV risk score).
Graph: Figure 1. There was trend for increase in SUA accross R-IPSET risk categories in essential thrombocythemia patients. The Jonckheere–Terpstra trend test was used. SUA: serum uric acid.
For the purpose of survival analyses, ROC curve with thrombosis as a classification variable was constructed to determine the optimal cutoff of SUA (>301 μmol/L). In univariate survival analyses, high SUA (HR 4.02, p < 0.001) (Figure 2), history of thrombosis (HR 9.69, p < 0.001), age >60 years (HR 5.47, p < 0.001), and the presence of CV risk factors (HR 4.47, p = 0.034) were associated with an increased risk of thrombosis. High SUA also had a negative prognostic impact on TFS when ET and PV patients were analyzed separately (HR 4.47, p = 0.004 and HR 3.94, p = 0.047, respectively). In the multivariate Cox proportional-hazards regression model, higher SUA remained independently associated with an inferior TFS, when adjusted for disease phenotype and classical ET and PV thrombosis-risk factors (Table 2), showing it possesses good additional prognostic properties. We then created another Cox regression model to further test whether high SUA still had an independent effect on TFS when adjusted for variables that differed at baseline (Table 1). In this model, high SUA remained prognostic for inferior TFS (HR 5.04, p = 0.024), when adjusted for JAK2 mutation (HR 7.13, p = 0.007), age >60 years (HR 4.57, p = 0.032), history of thrombosis (HR 7.01, p = 0.008), CV risk factors (HR 0.58, p = 0.446), hematocrit (HR 4.17, p = 0.041), hemoglobin (HR 3.34, p = 0.067), eGFR (HR 1.01, p = 0.313), creatinine (HR 0.33, p = 0.564), CRP (HR 0.12, p = 0.720), gout (HR 0.15, p = 0.699), and the presence of palpable splenomegaly (HR 1.00, p = 0.316).
Graph: Figure 2. Higher SUA in essential thrombocythemia and polycythemia vera patients was associated with an inferior TFS. SUA: serum uric acid; TFS: thrombosis-free survival.
Table 2. Higher SUA in essential thrombocythemia and polycythemia vera was associated with an increased risk of thrombosis in the multivariate Cox regression model.
Variable HR 95% CI SUA > 301 μmol/L 8.43 2.07–43.41 JAK2 mutation 7.14 0.09–0.69 History of thrombosis 5.34 1.16–6.33 Age > 60 years 6.97 2.04–124.38 CV risk factors 0.48 0.21–2.79 0.702 PV phenotype 0.61 0.16–2.34 0.486
- 4 SUA: serum uric acid; HR: hazard ratio; CI: confidence interval; JAK2: Janus Kinase 2; CV: cardiovascular; PV: polycythemia vera.
- 2 p values in bold-italic are statistically significant.
To the best of our knowledge, this is the first study to report independent prognostic properties of high SUA on thrombosis development in ET and PV patients. When interpreting our results, several interesting observations emerge from our study. First, as a continuous variable, SUA did not correlate with blood cell counts, which is in line with previously published reports [[
Third, associations of SUA with older age, higher CRP, higher creatinine, lower eGFR, and the presence of CV risk factors indicate that hyperuricemia, at least in part, might be induced by endothelial dysfunction, vascular aging, and subclinical inflammation that underlies CVD development in these disorders. Furthermore, chronic kidney disease (CKD) is an established risk factor for CVD in the general population [[
Limitations of this study are its retrospective design, single-center experience, and small number of patients included. Due to a small number of thrombotic events and a limited number of patients receiving allopurinol, we were unable to analyze the impact of anturicosuric treatment on thrombosis development.
In conclusion, our data suggest that high SUA (>301 μmol/L) at the time of ET and PV diagnosis might be JAK2, age, and history of thrombosis-independent risk factor for future CV events. Prospective controlled randomized trials are warranted to elucidate if more vigilant antiuricosuric treatment (i.e. with allopurinol or febuxostat) might improve outcomes in ET and PV patients.
No potential conflict of interest was reported by the author(s).
By Ivan Krečak; Marko Lucijanić; Velka Gverić-Krečak and Nadira Duraković
Reported by Author; Author; Author; Author